ARTES and Boehringer Ingelheim Animal Health Announce Collaboration
News Mar 17, 2015
ARTES Biotechnology has announced a collaboration with the global pharmaceutical company Boehringer Ingelheim Animal Health.
ARTES’ expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES’ METAVAX® platform, this offers a new, unique and very economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.
“This collaboration is another milestone in expanding our vaccine development expertise”, Michael Piontek, managing director of ARTES stated. “We are more than confident that our technology platform is perfectly suited for the development of safe and cost efficient vaccines that are highly relevant for the veterinary market.”
“Partnering is a central part of our strategy. We are excited about this collaboration and the opportunity to develop more innovative vaccines for the animal health market,” says Rolf-Dieter Günther, Head of Global Business Development and Licensing Animal Health for Boehringer Ingelheim.
With their ability to treat a wide a variety of diseases, spherical nucleic acids are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A team has developed a direct route to optimize these particles, bringing them one step closer to becoming a viable treatment option for numerous diseases, including cancer.READ MORE